Effect of Prophylactic Treatment with Intravesical Epirubicin on Recurrence of Superficial Bladder Cancer - The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG):: A Randomized Trial of Intravesical Epirubicin at Dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml

European Urology

Volumn 45, Issue 5, 2004, Pages 600-605

  Kuroda, Masao ^a   Niijima, Tadao ^b   Kotake, Toshihiko ^c   Akaza, Hideyuki ^d   Hinotsu, Shiro ^d  

^a NISSAY HOSPITAL   (Japan)

^b Senpo Tokyo Takanawa Hospital   (Japan)

^c Osaka Medical Center for Cancer and Cardiovascular   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Epirubicin; Intravesical instillation; Prophylaxis; Superficial bladder cancer

Indexed keywords

EPIRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER DYSFUNCTION; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; EPIRUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 1842687326     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.12.010     Document Type: Article

References (9)

1. The report of clinical statistical studies on registered bladder cancer patients in Japan 1994. Tokyo: Japanese Urological Association; 1997.
2. The report of clinical statistical studies on registered bladder cancer patients in Japan 1995. Tokyo: Japanese Urological Association; 1998.
3. The report of clinical statistical studies on registered bladder cancer patients in Japan 1996. Tokyo: Japanese Urological Association; 2000.
4. Akaza H., Isaka S., Koiso K., Kotake T., Machida T., Maru A.et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother. Pharmacol. 20(Suppl.):1987;S91-96.
5. Hinotsu S, Akaza H, Isaka S, Kagawa S, Koiso K, Kotake T, Machida T, Matsumura Y, Niijima T, Obata K, Ohashi Y, Ohe H, Shimazaki J, Tashiro K and The Japanese Urological Cancer Research Group for Adriamycin/Farmorubicin. Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer. Fifth Study of the Japanese Urological Cancer Research Group for Adriamycin/Farmorubicin. Gan To Kagaku Ryoho 2002;29(1):73-80.
6. Tarone R.E. Miscellanea: Tests for trend in life table analysis. Biometrika. 62:1975;679-682.
7. Hinotsu S., Akaza H., Ohashi Y., Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer. 86:1999;1818-1826.
8. Oosterlinck W., Kurth K.H., Schröder F., Bultinck J., Hammond B., Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol. 149:1993;749-752.
9. Kassinen E., Rintala E., Hellström P., Viitanen J., Juusela H., Rajala P.et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur. Urol. 42:2002;167-174.